The Pulmonary Drug Delivery Systems Market will reach US$53.269 billion in 2030 from US$43.182 billion in 2025 at a CAGR of 4.29% during the forecast period.
The increasing prevalence of the chronic respiratory disease worldwide will drive the market growth of the pulmonary drug delivery systems market during the forecast period. According to the World Health Organization, more than 1 billion people suffer from either acute or chronic respiratory conditions. Around 4 million people die prematurely from chronic respiratory diseases. In addition, nearly 235 million people suffer from asthma in the world and over 80% of the deaths due to Asthma occur in low and middle-income countries. The increasing incidence of such diseases will support the market growth as more patients will require the pulmonary drug delivery system for their treatment.
Moreover, the rapidly growing geriatric population worldwide will contribute to the market growth as they are more prone to chronic respiratory diseases such as bronchitis, tuberculosis, and chronic obstructive pulmonary disease, etc. which will surge the demand for pulmonary drug delivery systems in the market. The number of older persons is projected to double to 1.5 billion in 2050.
Furthermore, the growing health awareness and increasing investment in the healthcare and drug delivery industry by both public and private players are also expected to further fuel up the growth of the market. Also, the initiative taken by the governing bodies of various countries is increasing health awareness among the people. For instance, the National Asthma Control Program (NACP) by CDS, provides funds for educating asthma-affected patients. Such initiatives will encourage more patients to adopt pulmonary drug delivery systems for their treatment which will further strengthen the market growth during the forecast period.
By product, the dry powder inhalers (DPIs) segment is projected to hold a significant market share owing to the advantages such as short administration & preparation time, ease of use, and fewer irritant effects associated with the use of these inhalers. Geographically, North America holds a significant market share due to the increasing prevalence of chronic respiratory diseases, early adoption of the pulmonary drug delivery systems, and the surge in healthcare spending in the region. Asia Pacific will be the fastest-growing market region owing to the rapidly growing geriatric population, increasing adoption of an unhealthy lifestyle, and rising urbanization in the region.
The increase in the geriatric population across the globe is expected to drive the market growth of pulmonary drug delivery systems. According to COPD, about 1 in 7 older adults suffers from some of the other forms of lung disease. The geriatric population is more prone to chronic respiratory diseases as compared to the younger population which will increase the demand for pulmonary drug delivery systems in the market during the forecast period.
The pulmonary drug delivery system is a relatively new system due to which not many patients are aware of the advantages of using this system which may restrain the market growth during the forecast period. The patients, especially in the developing countries are unaware of the existence of this system due to which the demand for it is low in these countries. However, with the increasing awareness by both the public and private players the patients are expected to become aware and adopt these systems.
The global pulmonary drug delivery systems market report offers an in-depth analysis of the industry landscape, delivering strategic and executive-level insights backed by data-driven forecasts and analysis. This regularly updated report empowers decision-makers with actionable intelligence on current market trends, emerging opportunities, and competitive dynamics. It examines demand across various pulmonary drug delivery systems and technologies, such as metered-dose inhalers (MDIs), dry powder inhalers (DPIs), nebulizers, and soft mist inhalers, while also exploring applications and end-user segments, including hospitals, home care settings, and specialty clinics. Additionally, the report investigates technological advancements, key government policies, regulatory frameworks, and macroeconomic factors, providing a comprehensive view of the market.
Pulmonary Drug Delivery Systems Market Segmentation by Product:
The market is analyzed by product into the following:
Pulmonary Drug Delivery Systems Market Segmentation by Formulation Type:
The report analyzed the market by formulation type as below:
Pulmonary Drug Delivery Systems Market Segmentation by Application:
The market is analyzed by application into the following:
Pulmonary Drug Delivery Systems Market Segmentation by End-User Segment:
The report analyzed the market by end-user segment as below:
Pulmonary Drug Delivery Systems Market Segmentation by Distribution Channel Segment:
The report analyzed the market by distribution channel segment as below:
Pulmonary Drug Delivery Systems Market Segmentation by regions:
The study also analysed the pulmonary drug delivery systems market into the following regions, with country level forecasts and analysis as below:
The global pulmonary drug delivery systems market features key players such as Philips Respironics, GlaxoSmithKline PLC, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., 3M, PARI GmbH, F. Hoffmann-La Roche AG, Gilbert Technologies, AstraZeneca PLC, among others.
This report provides extensive coverage as explained in the points below:
How this report is helpful to you and reasons for purchase?
| Report Metric | Details |
|---|---|
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 β 2031 |
| Report Metric | Details |
| Pulmonary Drug Delivery Systems Market Size in 2025 | US$43.182 billion |
| Pulmonary Drug Delivery Systems Market Size in 2030 | US$53.269 billion |
| Growth Rate | CAGR of 4.29% |
| Study Period | 2020 to 2030 |
| Historical Data | 2020 to 2023 |
| Base Year | 2024 |
| Forecast Period | 2025 – 2030 |
| Forecast Unit (Value) | USD Billion |
| Segmentation |
|
| Geographical Segmentation | North America, South America, Europe, Middle East and Africa, Asia Pacific |
| List of Major Companies in the Pulmonary Drug Delivery Systems Market |
|
| Customization Scope | Free report customization with purchase |
Page last updated on: